+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zydus Cadila - logo

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

From
From
From
From
From
Antifungals Global Market Report 2020 - Product Thumbnail Image

Antifungals Global Market Report 2020

  • Report
  • November 2019
  • 200 Pages
From
Indian Generic Drug Market Outlook 2020 - Product Thumbnail Image

Indian Generic Drug Market Outlook 2020

  • Report
  • September 2015
  • 90 Pages
From
From
From
From
Global Diabetic Therapeutic Market 2017-2021 - Product Thumbnail Image

Global Diabetic Therapeutic Market 2017-2021

  • Report
  • February 2017
  • 167 Pages
From
From
Global Metabolic Disorders Therapeutics Market 2016-2020 - Product Thumbnail Image

Global Metabolic Disorders Therapeutics Market 2016-2020

  • Report
  • September 2016
  • 163 Pages
From
Biosimilars: Global Markets - Product Thumbnail Image

Biosimilars: Global Markets

  • Report
  • March 2018
  • 340 Pages
From
From
Typhoid Fever - Pipeline Insight, 2020 - Product Thumbnail Image

Typhoid Fever - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
Loading Indicator
adroll